120 related articles for article (PubMed ID: 1260757)
21. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
Cheever MA; Greenberg PD; Fefer A
Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulation and antitumor effects of MVE-2 in mice.
Talmadge JE; Maluish AE; Collins M; Schneider M; Herberman RB; Oldham RK; Wiltrout RH
J Biol Response Mod; 1984 Dec; 3(6):634-52. PubMed ID: 6334720
[TBL] [Abstract][Full Text] [Related]
23. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
[TBL] [Abstract][Full Text] [Related]
24. Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug.
Zunino F; Pratesi G; Pezzoni G
Cancer Treat Rep; 1987 Apr; 71(4):367-73. PubMed ID: 3829013
[TBL] [Abstract][Full Text] [Related]
25. Alteration of skin in Gross leukemia. IV. Test of allograft hypothesis.
Mariani T; Maruyama Y; Good RA
J Natl Cancer Inst; 1972 Sep; 49(3):879-85. PubMed ID: 4567230
[No Abstract] [Full Text] [Related]
26. In vivo modulation of myelopoiesis and immune functions by maleic anhydride divinyl ether copolymer (MVE-2) in tumor-free and MBL-2 tumor-bearing mice treated with cyclophosphamide.
Schlick E; Ruffmann R; Chirigos MA; Welker RD; Herberman RB
Cancer Res; 1985 Mar; 45(3):1108-14. PubMed ID: 3871661
[TBL] [Abstract][Full Text] [Related]
27. Effect of pyran copolymer on activation of murine macrophages: evidence for incomplete activation by use of functional markers.
Adams DO; Johnson WJ; Marino PA; Dean JH
Cancer Res; 1983 Aug; 43(8):3633-7. PubMed ID: 6861134
[TBL] [Abstract][Full Text] [Related]
28. Therapy of artificial and spontaneous metastases of murine tumors with maleic anhydride-divinyl ether-2.
Milas L; Hersh EM; Hunter N
Cancer Res; 1981 Jun; 41(6):2378-85. PubMed ID: 7237436
[TBL] [Abstract][Full Text] [Related]
29. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
30. Vaccination of adult and newborn mice of a resistant strain (C57BL/6J) against challenge with leukemias induced by Moloney murine leukemia virus.
Reif AE
Cancer Res; 1985 Jan; 45(1):25-31. PubMed ID: 3965136
[TBL] [Abstract][Full Text] [Related]
31. [Use of BCG as an immunoadjuvant in combination with antitumor agents in virus-induced leukemia].
Sbaraglia G; Cenci E; Vecchiarelli A; Perito S
Boll Soc Ital Biol Sper; 1980 Oct; 56(19):1969-75. PubMed ID: 7459108
[TBL] [Abstract][Full Text] [Related]
32. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection.
Li XC; Roy-Chaudhury P; Hancock WW; Manfro R; Zand MS; Li Y; Zheng XX; Nickerson PW; Steiger J; Malek TR; Strom TB
J Immunol; 1998 Jul; 161(2):890-6. PubMed ID: 9670967
[TBL] [Abstract][Full Text] [Related]
33. Effects of pyran copolymer on oncogenic virus infections in immunosuppressed hosts.
Hirsch MS; Black PH; Wood ML; Monaco AP
J Immunol; 1972 May; 108(5):1312-8. PubMed ID: 4337673
[No Abstract] [Full Text] [Related]
34. Drepression of nuclear template restrictions for DNA synthesis by the immunostimulator pyran copolymer.
Mohr SJ; Massicot JG; Chirigos MA
Cancer Res; 1978 Jun; 38(6):1610-6. PubMed ID: 647674
[No Abstract] [Full Text] [Related]
35. Tumor cell-related syngeneic skin graft rejection in gross leukemia.
Mariani T; Maruyama Y; Good RA
Natl Cancer Inst Monogr; 1972 Dec; 35():309-20. PubMed ID: 4572830
[No Abstract] [Full Text] [Related]
36. Stimulation of murine lymphocytes by Rauscher leukemia virus in vitro.
Bubbers JE; Elder JH; Dixon FJ
J Immunol; 1980 Jan; 124(1):388-94. PubMed ID: 7350233
[TBL] [Abstract][Full Text] [Related]
37. Effect of pyran copolymer on murine hemopoiesis.
Zander AR; Spitzer G; Verma DS; Beran M; Dicke KA
Exp Hematol; 1980 May; 8(5):521-6. PubMed ID: 7461054
[TBL] [Abstract][Full Text] [Related]
38. [Degree of proliferative response to concanavalin A of spleen cells of mice of different strains and production of interleukin-2].
Pukhal'skiĭ AL; Toptygina AP
Biull Eksp Biol Med; 1989 Aug; 108(8):238-40. PubMed ID: 2804334
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
40. Alteration of skin in gross leukemia. V. Refutation of virus involvement.
Mariani T; Maruyama Y
J Natl Cancer Inst; 1974 Dec; 53(6):1661-4. PubMed ID: 4612164
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
